Advances in mRNA non-viral delivery approaches

Friedmann, 1972, Gene therapy for human genetic disease?, Science, 175, 949, 10.1126/science.175.4025.949 Kaufmann, 2013, Gene therapy on the move, EMBO Mol. Med., 5, 1642, 10.1002/emmm.201202287 Mehier-Humbert, 2005, Physical methods for gene transfer: improving the kinetics of gene delivery into cells, Adv. Drug Deliv. Rev., 57, 733, 10.1016/j.addr.2004.12.007 Sahin, 2014, mRNA-based therapeutics–developing a new class of drugs, Nat. Rev. Drug Discov., 13, 759, 10.1038/nrd4278 Meng, 2017, A new developing class of gene delivery: messenger RNA-based therapeutics, Biomater. Sci., 5, 2381, 10.1039/C7BM00712D Wolff, 1990, Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 10.1126/science.1690918 Gomez-Aguado, 2020, Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives, Nanomaterials (Basel), 10, 10.3390/nano10020364 Shirley, 2020, Immune responses to viral gene therapy vectors, Mol. Ther., 28, 709, 10.1016/j.ymthe.2020.01.001 Patil, 2019, The development of functional non-viral vectors for gene delivery, Int. J. Mol. Sci., 20, 10.3390/ijms20215491 Sahu, 2019, Recent developments in mRNA-based protein supplementation therapy to target lung diseases, Mol. Ther., 27, 803, 10.1016/j.ymthe.2019.02.019 Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 Mandal, 2013, Reprogramming human fibroblasts to pluripotency using modified mRNA, Nat. Protoc., 8, 568, 10.1038/nprot.2013.019 Warren, 2010, Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA, Cell Stem Cell, 7, 618, 10.1016/j.stem.2010.08.012 Warren, 2019, mRNA-based genetic reprogramming, Mol. Ther., 27, 729, 10.1016/j.ymthe.2018.12.009 Heine, 2021, Clinical and immunological effects of mRNA vaccines in malignant diseases, Mol Cancer, 20, 52, 10.1186/s12943-021-01339-1 Wadhwa, 2020, Opportunities and challenges in the delivery of mRNA-based vaccines, Pharmaceutics, 12, 10.3390/pharmaceutics12020102 Martinon, 1993, Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA, Eur. J. Immunol., 23, 1719, 10.1002/eji.1830230749 Jackson, 2020, The promise of mRNA vaccines: a biotech and industrial perspective, npj Vaccines, 5, 11, 10.1038/s41541-020-0159-8 Park, 2021, Non-viral COVID-19 vaccine delivery systems, Adv. Drug Deliv. Rev., 169, 137, 10.1016/j.addr.2020.12.008 Faghfuri, 2021, Recent developments of RNA-based vaccines in cancer immunotherapy, Expert Opin. Biol. Ther., 21, 201, 10.1080/14712598.2020.1815704 Dorrie, 2020, Therapeutic cancer vaccination with Ex Vivo RNA-transfected dendritic cells-an update, Pharmaceutics, 12, 10.3390/pharmaceutics12020092 Miliotou, 2018, CAR T-cell Ttherapy: A new era in cancer immunotherapy, Curr. Pharm. Biotechnol., 19, 5, 10.2174/1389201019666180418095526 Pardi, 2018, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov., 17, 261, 10.1038/nrd.2017.243 Blakney, 2021, An update on self-amplifying mRNA vaccine development, Vaccines (Basel), 9 T.K.T. Mutzke, F. von der Mülbe, Lyophilization of nucleic acids in lactate-containing solutions, 2011. WO2011069528A1 T. Mutzke, Mannose-containing solution for lyophilization, transfection and/or injiection of nucleic acids, 2015. US20150141498A1 T.M. T. Ketterer, M. Wiggenhorn, F. Schaubhut, F. von der Mülbe, Lyophilization of RNA, 2016. WO2016165831A1 F.J.E. B.Y. Panah, S. Sewing, T. Ketterer, T. Murzke, Dry powder composition comprising long-chain RNA, 2016. WO2016184577 M.H.F.U. T. Kievits, F.H.M. Van Dinther, Freeze-dired composition comprising RNA, 1996. EP0702690A1 Zhao, 2020, Long-term storage of lipid-like nanoparticles for mRNA delivery, Bioact. Mater., 5, 358, 10.1016/j.bioactmat.2020.03.001 Crommelin, 2021, Addressing the cold reality of mRNA vaccine stability, J. Pharm. Sci., 110, 997, 10.1016/j.xphs.2020.12.006 Doudna, 2014, Genome editing. The new frontier of genome engineering with CRISPR-Cas9, Science, 346, 1258096, 10.1126/science.1258096 Zhang, 2019, Genome editing with mRNA encoding ZFN, TALEN, and Cas9, Mol. Ther., 27, 735, 10.1016/j.ymthe.2019.01.014 Gillmore, 2021, CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis, N. Engl. J. Med., 10.1056/NEJMoa2107454 Cheng, 2020, Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing, Nat. Nanotechnol., 15, 313, 10.1038/s41565-020-0669-6 Rosenblum, 2020, CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy, Sci. Adv., 6, 10.1126/sciadv.abc9450 Steinle, 2017, Concise review: application of in vitro transcribed messenger RNA for cellular engineering and reprogramming: progress and challenges, Stem Cells, 35, 68, 10.1002/stem.2402 Evdokimova, 2001, The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer, EMBO J., 20, 5491, 10.1093/emboj/20.19.5491 Haghighat, 1997, eIF4G dramatically enhances the binding of eIF4E to the mRNA 5'-cap structure, J. Biol. Chem., 272, 21677, 10.1074/jbc.272.35.21677 Chang, 2014, TAIL-seq: genome-wide determination of poly(A) tail length and 3' end modifications, Mol. Cell, 53, 1044, 10.1016/j.molcel.2014.02.007 Holtkamp, 2006, Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells, Blood, 108, 4009, 10.1182/blood-2006-04-015024 Durymanov, 2018, Non-viral delivery of nucleic acids: insight into mechanisms of overcoming intracellular barriers, Front. Pharmacol., 9, 971, 10.3389/fphar.2018.00971 Ke, 2021, Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs), Adv. Drug Deliv. Rev., 113835 Johnson, 2021, Nucleic acid nanoparticles (NANPs) as molecular tools to direct desirable and avoid undesirable immunological effects, Adv. Drug Deliv. Rev., 173, 427, 10.1016/j.addr.2021.04.011 Chen, 2017, RNA sensors of the innate immune system and their detection of pathogens, IUBMB Life, 69, 297, 10.1002/iub.1625 Badieyan, 2019, Concise Review: Application of Chemically Modified mRNA in Cell Fate Conversion and Tissue Engineering, Stem Cells Transl Med, 8, 833, 10.1002/sctm.18-0259 Kariko, 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr. Opin. Drug Discov. Devel., 10, 523 Baum, 2006, Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors, Hum. Gene Ther., 17, 253, 10.1089/hum.2006.17.253 Bulcha, 2021, Viral vector platforms within the gene therapy landscape, Signal Transduct Target Ther, 6, 53, 10.1038/s41392-021-00487-6 Raper, 2003, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80, 148, 10.1016/j.ymgme.2003.08.016 Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Invest., 118, 3143, 10.1172/JCI35798 Alexis, 2008, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm., 5, 505, 10.1021/mp800051m Field, 2015, Peptides for specifically targeting nanoparticles to cellular organelles: quo vadis?, Acc. Chem. Res., 48, 1380, 10.1021/ar500449v Lou, 2019, mRNA polyplexes with post-conjugated GALA peptides efficiently target, transfect, and activate antigen presenting cells, Bioconjug Chem, 30, 461, 10.1021/acs.bioconjchem.8b00524 Salvati, 2013, Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nat. Nanotechnol., 8, 137, 10.1038/nnano.2012.237 Lorenz, 2011, Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway, RNA Biol., 8, 627, 10.4161/rna.8.4.15394 Wu, 2021, Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines: challenges and future perspectives, Pharm. Res., 10.1007/s11095-021-03015-x Aldosari, 2021, Lipid nanoparticles as delivery systems for RNA-based vaccines, Pharmaceutics, 13, 10.3390/pharmaceutics13020206 Guevara, 2020, Advances in lipid nanoparticles for mRNA-based cancer immunotherapy, Front. Chem., 8, 10.3389/fchem.2020.589959 Slivac, 2017, Non-viral nucleic acid delivery methods, Expert Opin. Biol. Ther., 17, 105, 10.1080/14712598.2017.1248941 Landesman-Milo, 2014, Toxicity profiling of several common RNAi-based nanomedicines: a comparative study, Drug Deliv. Transl. Res., 4, 96, 10.1007/s13346-013-0158-7 Ma, 2005, Cationic lipids enhance siRNA-mediated interferon response in mice, Biochem. Biophys. Res. Commun., 330, 755, 10.1016/j.bbrc.2005.03.041 Platanias, 2005, Mechanisms of type-I- and type-II-interferon-mediated signalling, Nat. Rev. Immunol., 5, 375, 10.1038/nri1604 Lv, 2006, Toxicity of cationic lipids and cationic polymers in gene delivery, J. Control. Release, 114, 100, 10.1016/j.jconrel.2006.04.014 Kulkarni, 2018, Lipid nanoparticles enabling gene therapies: from concepts to clinical utility, Nucleic Acid Ther., 28, 146, 10.1089/nat.2018.0721 Hafez, 2001, On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids, Gene Ther., 8, 1188, 10.1038/sj.gt.3301506 Zelphati, 1996, Mechanism of oligonucleotide release from cationic liposomes, Proc. Natl. Acad. Sci. U S A, 93, 11493, 10.1073/pnas.93.21.11493 Thess, 2015, Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals, Mol. Ther., 23, 1456, 10.1038/mt.2015.103 Ramaswamy, 2017, Systemic delivery of factor IX messenger RNA for protein replacement therapy, Proc. Natl. Acad. Sci. U S A, 114, E1941, 10.1073/pnas.1619653114 J.M. Richner, S. Himansu, K.A. Dowd, S.L. Butler, V. Salazar, J.M. Fox, J.G. Julander, W.W. Tang, S. Shresta, T.C. Pierson, G. Ciaramella, M.S. Diamond, Modified mRNA Vaccines Protect against Zika Virus Infection, Cell, 168 (2017) 1114-1125 e1110. Bahl, 2017, Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses, Mol. Ther., 25, 1316, 10.1016/j.ymthe.2017.03.035 Buschmann, 2021, Nanomaterial delivery systems for mRNA vaccines, Vaccines (Basel), 9 Allen, 2013, Liposomal drug delivery systems: from concept to clinical applications, Adv. Drug Deliv. Rev., 65, 36, 10.1016/j.addr.2012.09.037 Takahashi, 1996, Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine, Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids, 1289, 209, 10.1016/0304-4165(95)00170-0 Zuhorn, 2005, Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency, Mol. Ther., 11, 801, 10.1016/j.ymthe.2004.12.018 Cheng, 2016, The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery, Adv. Drug Deliv. Rev., 99, 129, 10.1016/j.addr.2016.01.022 Jokerst, 2011, Nanoparticle PEGylation for imaging and therapy, Nanomedicine (Lond), 6, 715, 10.2217/nnm.11.19 Li, 2010, Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting, J. Control. Release, 145, 178, 10.1016/j.jconrel.2010.03.016 Martinez-Pomares, 2012, The mannose receptor, J. Leukoc. Biol., 92, 1177, 10.1189/jlb.0512231 Geijtenbeek, 2000, Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses, Cell, 100, 575, 10.1016/S0092-8674(00)80693-5 Jiang, 1995, The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing, Nature, 375, 151, 10.1038/375151a0 Valladeau, 2000, Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules, Immunity, 12, 71, 10.1016/S1074-7613(00)80160-0 Akinc, 2005, Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis, J. Gene Med., 7, 657, 10.1002/jgm.696 Zhao, 2016, Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA, Drug Deliv., 23, 2596, 10.3109/10717544.2015.1038856 Li, 2016, Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways, J. Control. Release, 228, 9, 10.1016/j.jconrel.2016.02.043 Li, 2017, Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses, Acta Biomater., 64, 237, 10.1016/j.actbio.2017.10.019 Tan, 2020, Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates, Drug Deliv. Transl. Res., 10, 678, 10.1007/s13346-020-00725-4 Sharifnia, 2019, In-vitro transcribed mRNA delivery using PLGA/PEI nanoparticles into human monocyte-derived dendritic cells, Iran J. Pharm. Res., 18, 1659 Hamada, 2021, Anionic complex with efficient expression and good safety profile for mRNA delivery, Pharmaceutics, 13, 10.3390/pharmaceutics13010126 Aini, 2016, Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment, Sci. Rep., 6, 18743, 10.1038/srep18743 Baba, 2015, Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles, J. Control. Release, 201, 41, 10.1016/j.jconrel.2015.01.017 Chen, 2017, A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors, Mol. Ther., 25, 92, 10.1016/j.ymthe.2016.10.006 Crowley, 2019, Enhancement of motor function recovery after spinal cord injury in mice by delivery of brain-derived neurotrophic factor mRNA, Mol. Ther. Nucleic Acids, 17, 465, 10.1016/j.omtn.2019.06.016 Matsui, 2015, Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases, Sci. Rep., 5, 15810, 10.1038/srep15810 Uchida, 2016, Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety, Biomaterials, 82, 221, 10.1016/j.biomaterials.2015.12.031 Chan, 2019, Preparation of messenger RNA nanomicelles via non-cytotoxic PEG-polyamine nanocomplex for intracerebroventicular delivery: A proof-of-concept study in mouse models, Nanomaterials (Basel), 9, 10.3390/nano9010067 Miyazaki, 2020, Polymeric nanocarriers with controlled chain flexibility boost mRNA delivery in vivo through enhanced structural fastening, Adv. Healthc. Mater., 9 Balhorn, 2007, The protamine family of sperm nuclear proteins, Genome Biol., 8, 227, 10.1186/gb-2007-8-9-227 Jarzebska, 2020, Functional differences between protamine preparations for the transfection of mRNA, Drug Deliv, 27, 1231, 10.1080/10717544.2020.1790692 Scheel, 2005, Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA, Eur. J. Immunol., 35, 1557, 10.1002/eji.200425656 Rettig, 2010, Particle size and activation threshold: a new dimension of danger signaling, Blood, 115, 4533, 10.1182/blood-2009-11-247817 Sebastian, 2019, A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer, Cancer Immunol. Immunother., 68, 799, 10.1007/s00262-019-02315-x Kubler, 2015, Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study, J. ImmunoTher. Cancer, 3, 26, 10.1186/s40425-015-0068-y Armbruster, 2019, Advances in RNA vaccines for preventive indications: A case study of A vaccine against rabies, Vaccines (Basel), 7 Ye, 2016, CPP-assisted intracellular drug delivery, what is next?, Int. J. Mol. Sci., 17, 10.3390/ijms17111892 Derakhshankhah, 2018, Cell penetrating peptides: A concise review with emphasis on biomedical applications, Biomed. Pharmacother., 108, 1090, 10.1016/j.biopha.2018.09.097 Ziegler, 2008, Binding and clustering of glycosaminoglycans: a common property of mono- and multivalent cell-penetrating compounds, Biophys. J ., 94, 2142, 10.1529/biophysj.107.113472 Frankel, 1988, Cellular uptake of the tat protein from human immunodeficiency virus, Cell, 55, 1189, 10.1016/0092-8674(88)90263-2 van den Brand, 2019, Peptide-mediated delivery of therapeutic mRNA in ovarian cancer, Eur. J. Pharm. Biopharm., 141, 180, 10.1016/j.ejpb.2019.05.014 Udhayakumar, 2017, Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide, Adv. Healthc. Mater., 6, 10.1002/adhm.201601412 McCarthy, 2014, Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery, J. Control. Release, 189, 141, 10.1016/j.jconrel.2014.06.048 Zhang, 2008, Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform, ACS Nano, 2, 1696, 10.1021/nn800275r Hadinoto, 2013, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, Eur. J. Pharm. Biopharm., 85, 427, 10.1016/j.ejpb.2013.07.002 Liu, 2020, Advances in next-generation lipid-polymer hybrid nanocarriers with emphasis on polymer-modified functional liposomes and cell-based-biomimetic nanocarriers for active ingredients and fractions from Chinese medicine delivery, Nanomedicine, 29 Zhao, 2018, Lipid polymer hybrid nanomaterials for mRNA delivery, Cell. Mol. Bioeng., 11, 397, 10.1007/s12195-018-0536-9 Islam, 2018, Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA, Nat. Biomed. Eng., 2, 850, 10.1038/s41551-018-0284-0 Kaczmarek, 2016, Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs, Angew. Chem. Int. Ed. Engl., 55, 13808, 10.1002/anie.201608450 Zohra, 2009, High performance mRNA transfection through carbonate apatite-cationic liposome conjugates, Biomaterials, 30, 4006, 10.1016/j.biomaterials.2009.02.050 Wang, 2013, Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy, Mol. Ther., 21, 358, 10.1038/mt.2012.250 Choi, 2016, Efficient mRNA delivery with graphene oxide-polyethylenimine for generation of footprint-free human induced pluripotent stem cells, J. Control. Release, 235, 222, 10.1016/j.jconrel.2016.06.007 Valadi, 2007, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nat. Cell Biol., 9, 654, 10.1038/ncb1596 Garofalo, 2018, Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies, Viruses, 10, 10.3390/v10100558 Pinheiro, 2018, Extracellular vesicles: intelligent delivery strategies for therapeutic applications, J. Control. Release, 289, 56, 10.1016/j.jconrel.2018.09.019 O'Brien, 2020, RNA delivery by extracellular vesicles in mammalian cells and its applications, Nat. Rev. Mol. Cell Biol., 21, 585, 10.1038/s41580-020-0251-y Skog, 2008, Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers, Nat. Cell Biol., 10, 1470, 10.1038/ncb1800 Maugeri, 2019, Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells, Nat. Commun., 10, 4333, 10.1038/s41467-019-12275-6 Usman, 2018, Efficient RNA drug delivery using red blood cell extracellular vesicles, Nat. Commun., 9, 2359, 10.1038/s41467-018-04791-8 Yang, 2020, Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation, Nat. Biomed. Eng., 4, 69, 10.1038/s41551-019-0485-1 Sun, 2020, Ultrasound assisted exosomal delivery of tissue responsive mRNA for enhanced efficacy and minimized off-target effects, Mol. Ther. Nucleic Acids, 20, 558, 10.1016/j.omtn.2020.03.016 Luan, 2017, Engineering exosomes as refined biological nanoplatforms for drug delivery, Acta Pharmacol. Sin., 38, 754, 10.1038/aps.2017.12